#Spain #Ulcerative Colitis #Barcelona #AC-101 #Accro Bioscience

Accro Bioscience to Present Phase Ib Data of AC-101 at UEG Week 2026

Accro Bioscience, a biotechnology firm focused on innovative treatments for immune-mediated conditions, has announced an important presentation at UEG Week 2026, which will be held from October 17 to 20 in Barcelona, Spain. The company aims to showcase the efficacy and safety results from its Phase Ib proof-of-concept study of AC-101, an oral selective inhibitor targeting RIPK2, for patients suffering from moderate-to-severe ulcerative colitis (UC).

Study Overview

The upcoming presentation, which includes an abstract type, an e-poster, and a live presentation, will share crucial findings regarding how AC-101 performs as an induction therapy for this challenging condition. The abstract has been assigned the ID AS-UEG-2026-03820, and its title emphasizes the focus on both efficacy and safety outcomes achieved during the study. The presenting author is Professor Ren Mao from The First Affiliated Hospital of Sun Yat-sen University, a recognized figure in this area of research.

Timing and Location

The UEG Week is a significant event for experts in gastrointestinal health, where innovations and research outcomes are unveiled. Accro's findings are expected to attract attention, considering the growing demand for effective treatments for UC, a chronic inflammatory bowel disease characterized by inflammation and ulcers in the colon.

What is AC-101?

AC-101 is notable as it marks a new approach in the treatment landscape for moderate-to-severe UC. Specifically, it is a selective RIPK2 inhibitor developed to mitigate the pathological processes associated with UC. Research has indicated that RIPK2 plays a critical role in the NOD signaling pathway, which is frequently dysregulated in various inflammatory and autoimmune diseases. As such, targeting this pathway with a selective inhibitor represents a promising therapeutic avenue.

Accro Bioscience has utilized its proprietary drug discovery platform to develop AC-101. Initial Phase I studies conducted in healthy volunteers across Australia and China have demonstrated favorable safety profiles, alongside pharmacokinetic and pharmacodynamic characteristics that underpin its potential as a treatment option.

Future Clinical Trials

Encouragingly, the company has already received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to advance AC-101 into Phase II clinical trials. This clearance speaks volumes about the regulatory confidence in the drug's initial safety and the need for an effective treatment alternative for UC patients.

About Accro Bioscience

Accro Bioscience, headquartered in both New York and Suzhou, China, is committed to the discovery and development of novel therapeutics targeting the underlying biological mechanisms driving inflammatory and autoimmune diseases. The company's pipeline includes a range of first- and best-in-class compounds designed to address significant medical needs in these fields. Accro's goal is to transform treatments and improve patient outcomes through innovative research and development.

For more information about their ongoing studies and therapeutic approaches, interested individuals and media can visit Accro Bioscience's official website. The company's advancements underscore the importance of continued research into autoimmune conditions and the quest for effective therapies that can provide relief and improvement in patients' lives.